Cellectar Biosciences Past Earnings Performance
We're still processing the latest earnings report of this company
Past criteria checks 0/6
Cellectar Biosciences's earnings have been declining at an average annual rate of -24.7%, while the Biotechs industry saw earnings growing at 13.4% annually.
Key information
-24.7%
Earnings growth rate
53.7%
EPS growth rate
Biotechs Industry Growth | -14.6% |
Revenue growth rate | n/a |
Return on equity | -194.8% |
Net Margin | n/a |
Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cellectar Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 0 | -51 | 13 | 29 |
31 Dec 23 | 0 | -38 | 11 | 28 |
30 Sep 23 | 0 | -38 | 8 | 26 |
30 Jun 23 | 0 | -32 | 8 | 24 |
31 Mar 23 | 0 | -31 | 9 | 22 |
31 Dec 22 | 0 | -29 | 10 | 19 |
30 Sep 22 | 0 | -27 | 9 | 18 |
30 Jun 22 | 0 | -25 | 9 | 17 |
31 Mar 22 | 0 | -24 | 7 | 17 |
31 Dec 21 | 0 | -24 | 7 | 18 |
30 Sep 21 | 0 | -22 | 6 | 16 |
30 Jun 21 | 0 | -20 | 6 | 14 |
31 Mar 21 | 0 | -17 | 6 | 12 |
31 Dec 20 | 0 | -15 | 5 | 10 |
30 Sep 20 | 0 | -15 | 5 | 10 |
30 Jun 20 | 0 | -15 | 5 | 10 |
31 Mar 20 | 0 | -14 | 5 | 9 |
31 Dec 19 | 0 | -14 | 5 | 9 |
30 Sep 19 | 0 | -15 | 5 | 8 |
30 Jun 19 | 0 | -16 | 5 | 7 |
31 Mar 19 | 0 | -16 | 5 | 7 |
31 Dec 18 | 0 | -15 | 5 | 7 |
30 Sep 18 | 0 | -17 | 5 | 9 |
30 Jun 18 | 0 | -15 | 5 | 9 |
31 Mar 18 | 0 | -16 | 5 | 10 |
31 Dec 17 | 0 | -15 | 4 | 9 |
30 Sep 17 | 0 | -15 | 4 | 8 |
30 Jun 17 | 0 | -14 | 4 | 7 |
31 Mar 17 | 0 | -13 | 5 | 6 |
31 Dec 16 | 0 | -9 | 5 | 5 |
30 Sep 16 | 0 | -3 | 4 | 4 |
30 Jun 16 | 0 | -2 | 4 | 4 |
31 Mar 16 | 0 | -2 | 3 | 5 |
31 Dec 15 | 0 | -5 | 3 | 5 |
30 Sep 15 | 0 | -10 | 3 | 6 |
30 Jun 15 | 0 | -8 | 3 | 6 |
31 Mar 15 | 0 | -7 | 4 | 6 |
31 Dec 14 | 0 | -8 | 4 | 6 |
30 Sep 14 | 0 | -9 | 4 | 6 |
30 Jun 14 | 0 | -10 | 4 | 7 |
31 Mar 14 | 0 | -10 | 4 | 7 |
31 Dec 13 | 0 | -11 | 4 | 7 |
Quality Earnings: NV4 is currently unprofitable.
Growing Profit Margin: NV4 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NV4 is unprofitable, and losses have increased over the past 5 years at a rate of 24.7% per year.
Accelerating Growth: Unable to compare NV4's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NV4 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: NV4 has a negative Return on Equity (-194.85%), as it is currently unprofitable.